Muscle-specific receptor tyrosine kinase (MuSK) myasthenia gravis associated with castleman disease

Jeeyoung Oh; Woo Ick Yang; Jeong Hoon Cho; Il Nam Sunwoo

doi:10.14253/acn.2017.19.1.74

Journal List > Ann Clin Neurophysiol > v.19(1) > 1099508

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Oh, Yang, Cho, and Sunwoo: Muscle-specific receptor tyrosine kinase (MuSK) myasthenia gravis associated with castleman disease

Original Article

Ann Clin Neurophysiol 2017;19(1):74-76.

Published online: 5 January 2017

DOI: https://doi.org/10.14253/acn.2017.19.1.74

Muscle-specific receptor tyrosine kinase (MuSK) myasthenia gravis associated with castleman disease

Jeeyoung Oh¹, Woo Ick Yang², Jeong Hoon Cho³, Il Nam Sunwoo⁴

¹Department of Neurology, Konkuk University School of Medicine, Seoul, Korea

²Department of Pathology, Yonsei University College of Medicine, Seoul, Korea

³Purunsol Neurology Clinic, Incheon, Korea

⁴Sunwoo & Cho Neurology Clinic, Seoul, Korea

Correspondence to Il Nam Sunwoo Sunwoo & Cho Neurology Clinic, S/W building, 320 Toegye-ro, Jung-gu, Seoul 04614, Korea Tel: +82-2-2268-1400 Fax: +82-2-2268-4400 E-mail: sunwooin@yuhs.ac

Received 8 November 201616 December 2016 Accepted 20 December 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

초록

Muscle specific tyrosine kinase (MuSK) myasthenia gravis (MG) is a rare subtype of MG, which is immunologically distinct and differential therapeutic response. Though MG is often associated with other autoimmune disorders or malignancy, concurrence of other disease and MuSK MG has been infrequently reported. We present a patient of MuSK MG associated with multicentric Castelman disease.

Keywords: Castleman disease, Myasthenia gravis, Muscle specific tyrosine kinase

REFERENCES

1.Dispenzieri A., Armitage JO., Loe MJ., Geyer SM., Allred J., Camori-ano JK, et al. The clinical spectrum of Castleman's disease. Am J Hematol. 2012. 87:997–1002.

2.Day JR., Bew D., Ali M., Dina R., Smith PL. Castleman's disease associated with myasthenia gravis. Ann Thorac Surg. 2003. 75:1648–1650.

3.Chorzelski T., Hashimoto T., Maciejewska B., Amagai M., Anhalt GJ., Jablonska S. Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans. J Am Acad Dermatol. 1999. 41:393–400.

4.Wang HW., Pittaluga S., Jaffe ES. Multicentric Castleman disease: where are we now? Semin Diagn Pathol. 2016. 33:294–306.

5.Cheuk W., Chan JK. Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity. Semin Diagn Pathol. 2012. 29:226–234.

6.Hurst RL., Gooch CL. Muscle-specific receptor tyrosine kinase (MuSK) myasthenia gravis. Curr Neurol Neurosci Rep. 2016. 16:61.

7.Oh SJ. Muscle-Specific receptor tyrosine kinase antibody positive myasthenia gravis current status. J Clin Neurol. 2009. 5:53–64.

8.Sylvester J., Purdie G., Slee M., Gray JX., Burnet S., Koblar S. Muscle-specific kinase antibody positive myaesthenia gravis and multiple sclerosis co-presentation: a case report and literature review. J Neuroimmunol. 2013. 264:130–133.

Fig. 1.

Cervical lymph node biopsy demonstrates (A) lymphoid follicle hyperplasia with interfollicular sheets of plasma cells (hematoxylin and eosin statin; original magnification ×100) (B) which are positive in CD138 (immunohistochemical stain for CD138; original magnification ×200).

TOOLS

Similar articles